Migraine Treatment Outcome Measures vs Aesthetic Endpoints: Two Assessment Frameworks

Migraine treatment outcome measures have almost nothing in common with the way you assess an aesthetic neurotoxin result, and injectors who move into therapeutic work carry the wrong framework across more often than they carry the wrong technique. Setting a measurable goal is, to me, one of the most important parts of this whole process — and it is the step that gets skipped, because in aesthetics the outcome is visible and nobody has ever needed to define it in advance.

Here the outcome is invisible, it lives in the patient's month rather than in their face, and if you have not defined it before the first injection you will never be able to settle the question of whether this worked.

Two frameworks, side by side

In aesthetics we assess dynamic movement, facial symmetry, and the patient's aesthetic concern, and we tailor the treatment to them. The assessment is visual, it is performed in the room, it is largely the clinician's judgement, and it resolves within two weeks of the injection.

In headache we assess the frequency, duration, severity and location of attacks, and above all disease burden — how many hours a day can this person function, how many hours are they losing to headache, and can we move that number at all. The assessment is quantitative, it is performed on data the patient collects between visits, it is largely the patient's report, and it resolves over months.

Every axis is different. In-room versus between-visit. Clinician-observed versus patient-recorded. Qualitative versus counted. Two weeks versus three cycles. There is no version of the aesthetic method that gets you a therapeutic answer.

Why the aesthetic framework fails here, concretely

Picture two patients three months after treatment.

The first has beautifully quiet corrugators, a smooth upper face, and no asymmetry. She has also had eleven headache days this month, down from twelve. By the aesthetic framework she is an excellent result. She is a treatment failure.

The second has visible residual movement, because you injected for sensory coverage rather than for motor effect and some of the anterior dose went where the lines are not. He has gone from eighteen headache days to seven and is back at work. By the aesthetic framework he looks under-dosed. He is exactly what you were trying to achieve.

The aesthetic assessment is not a weak proxy for the therapeutic one. It is an assessment of a different organ system, and it will mislead you in both directions.

Set the goal before the first injection

This is the operational instruction that matters most in this article. The measurable goal must exist in the chart before any drug goes in, for three separate reasons.

It establishes eligibility. It creates the baseline you will subtract from. And it removes the single worst conversation in this treatment — the one at week twelve where the patient says "I think maybe a bit better?" and you have nothing to compare it to except two people's recollection of how bad March was.

ICHD-3 states that characterising frequently recurring headache "generally requires a headache diary to record information on pain and associated symptoms day-by-day for at least one month." Treat that as the minimum. Twenty-eight days of prospective data, collected before you treat.

The four domains worth recording

Use a 28-day denominator throughout, because that is what the trial data use and it removes the distortion of comparing a 28-day February to a 31-day March.

1. Frequency

Headache days per 28 days is the primary measure. It was the primary endpoint of the PREEMPT pivotal programme, where mean change from baseline at week 24 was −7.8 versus −6.4 in Study 1 and −9.2 versus −6.9 in Study 2, active versus placebo (BOTOX prescribing information, Clinical Studies).

Record migraine or probable migraine days separately from total headache days. The two counts answer different questions — eligibility turns partly on the migraine-feature day count, while response is judged on total headache days — and a single blended number loses both.

2. Duration and burden

Total cumulative hours of headache on headache days was a formal secondary endpoint in both pivotal trials, with mean changes from baseline of −107 versus −70 in Study 1 and −134 versus −95 in Study 2. It is a genuinely better measure of lived burden than a day count, because a day with two hours of headache and a day with fourteen count identically in the frequency column.

Alongside it, record the thing Dr. Croley asks about directly: functional hours. How many hours a day can they function, and how many are they losing. That is the number patients actually care about, and it is the one that converts a clinical result into a reason to continue treatment.

3. Severity

Moderate-to-severe headache days per 28 days, counted separately. A patient who trades six severe days for six mild ones has improved substantially while their headache-day count sits still.

Record acute medication intake days in the same column. It doubles as a severity proxy and as your medication-overuse surveillance, which matters because overuse is the most common cause of symptoms that look like chronic migraine.

4. Impact and function

Use a validated instrument rather than an impression. The Headache Impact Test (HIT-6) is the one embedded in this evidence base: a ≥5-point improvement was one of the four responder definitions used in the PREEMPT per-cycle responder analysis (Silberstein SD, Dodick DW, Aurora SK, et al. Per cent of patients with chronic migraine who responded per onabotulinumtoxinA treatment cycle: PREEMPT. J Neurol Neurosurg Psychiatry. 2015;86(9):996–1001).

European consensus guidance takes the same position on what a practice should minimally collect: headache days as the baseline metric, supplemented by HIT-6, with patients documenting headache frequency and acute medication use in headache calendars (Bendtsen L, Sacco S, Ashina M, et al. Guideline on the use of onabotulinumtoxinA in chronic migraine: a consensus statement from the European Headache Federation. J Headache Pain. 2018;19(1):91).

Pick your responder threshold in advance

A threshold chosen after the data arrive is not a threshold, it is a negotiation. Pick one and write it in the chart at baseline. The four used in the published per-cycle analysis are all defensible:

• ≥50% reduction in headache-day frequency
• ≥50% reduction in moderate/severe headache days
• ≥50% reduction in total cumulative hours of headache
• ≥5-point improvement in HIT-6

I would record all four and nominate one as the decision variable. They do not always move together, and a patient who fails on headache days but gains eight HIT-6 points has told you something real.

Then set both ends of the stopping rule, out loud, before you start. The EHF consensus recommends stopping if the patient does not respond to the first two to three treatment cycles, and also identifies the other end — a sustained reduction to fewer than ten headache days a month for three months. Symmetry here is a kindness: patients accept "we will stop if this is not working" far more readily when they have also been told what success would look like.

Pattern data is diagnostic, not an outcome

Separately from the outcome columns, capture the shape of the headaches: what triggers them, when they start, whether they localise to one area, whether they are unilateral.

This is not how you measure success. It is how you notice a problem. A change in the pattern, the character, the location or the associated symptoms of a previously stable headache is a recognised red flag for a secondary cause, and it is the one thing in your dataset that should stop a treatment cycle rather than adjust it. That is covered in detail in the companion resource on secondary-headache red flags; here the instruction is simply to record the pattern at baseline so that a change is visible when it happens.

The aesthetic examination still has a job — a different one

None of this means the physical examination disappears. It moves from the efficacy column to the safety column.

Before treatment, each patient should be examined for preexisting eyelid ptosis, brow ptosis, pseudoptosis of the eyelids, neck pain and neck weakness, because these change what you should warn them about and what you will have to distinguish from a treatment effect later. Patients with chronic migraine may have preexisting neck pain or weakness, and patients with small frames may be predisposed to weakness after posterior injection (Blumenfeld AM, Silberstein SD, Dodick DW, Aurora SK, Brin MF, Binder WJ. Insights into the Functional Anatomy Behind the PREEMPT Injection Paradigm. Headache. 2017;57(5):766–777).

So the movement examination you already know how to perform is still worth performing. It is now a baseline for adverse events, not a measure of whether the treatment worked. Empire's material on dynamic versus static wrinkles and the Botox face chart describes the assessment in its original aesthetic context; the skill transfers, the purpose does not.

What to do differently on Monday

• Build a one-page baseline sheet and refuse to inject without it.
• Use 28 days, always, for every count.
• Record five numbers per cycle: headache days, migraine days, cumulative headache hours, moderate/severe days, acute medication days. Add a HIT-6 score.
• Ask "how many hours a day can you function" and write the answer down. It is the number that keeps patients in treatment.
• Nominate one responder threshold at baseline and state the stopping rule in both directions.
• Record the headache pattern at baseline so that a change in it is detectable.
• Keep doing the physical exam, and be clear with yourself that it is now a safety baseline.

Assessment, facial anatomy and neurotoxin technique are taught hands-on in Empire's Cosmetic Neurotoxins Training and Complete Facial Aesthetic Training workshops.

This assessment framework reflects Dr. Chris Croley's clinical practice as taught in Empire Medical Training's hands-on curriculum, together with the trial endpoints, labelling and consensus guidance cited above. This article is educational and is not a substitute for training.

Related guides in this cluster

Part of Therapeutic Neurotoxin: Chronic Migraine.

Clinical GuideChronic Migraine On-Label Criteria: Deciding Which Patients Actually QualifyChronic migraine criteria decide who you can treat on-label. The label wording, the ICHD-3 definition, the diary, and the documentation Clinical GuideConfirm the Diagnosis First: Secondary-Headache Red Flags Before You InjectSecondary headache red flags decide whether a migraine patient gets injected or referred. The SNNOOP10 framework, the numbers behind it Clinical GuideThe PREEMPT Protocol: Why Fixed-Site, Fixed-Dose Was the Trial Design, and What It Means in PracticeThe PREEMPT protocol is fixed-site, fixed-dose for a reason. What the trial design was, why the label is rigid, and where tailoring is